Differential diagnosis and treatment of jaundice after comprehensive treatment of advanced primary liver cancer: A case report

Si XIE; Ming YANG; Yuan HUANG; Lai WEI

doi:10.3969/j.issn.1001-5256.2021.02.030

Volume 37 Issue 2

Mar. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(2): 400-402

PDF( 2088 KB)

Differential diagnosis and treatment of jaundice after comprehensive treatment of advanced primary liver cancer: A case report

DOI: 10.3969/j.issn.1001-5256.2021.02.030

Si XIE¹,
Ming YANG¹,
Yuan HUANG¹,
Lai WEI^{2
,
,}

1.
Department of Hepatology, Hepato-pancreato-biliary Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China
2.
Hepato-pancreato-biliary Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 102218, China

Received Date: 2020-07-13
Accepted Date: 2020-09-19
Published Date: 2021-02-20

Abstract

- Liver Neoplasms,
- Jaundice,
- Diagnosis, Differential,
- Combined Modality Therapy

FullText(HTML)

References(10)

References

[1]	Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.02.007 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007
[2]	MINAMI Y, KUDO M. Hepatocellular carcinoma with obstructive jaundice: Endoscopic and percutaneous biliary drainage[J]. Dig Dis, 2012, 30(6): 592-597. DOI: 10.1159/000343087
[3]	YU H, GUO Z, XING W, et al. Bile culture and susceptibility testing of malignant biliary obstruction via PTBD[J]. Cardiovasc Intervent Radiol, 2012, 35(5): 1136-1144. DOI: 10.1007/s00270-011-0263-2
[4]	KUDO M, FINN RS, QIN S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173. DOI: 10.1016/S0140-6736(18)30207-1
[5]	Chinese Society of Clinical Oncology Guidance Working Committee. Guidelines of Chinese Society of Clinical Oncology (CSCO) management of immune checkpoint inhibitor-related toxicity[M]. Beijing: People's Medical Publishing House, 2019: 33-36. (in Chinese) 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)免疫检查点抑制剂相关的毒性管理指南2019[M]. 北京:人民卫生出版社, 2019: 33-36.
[6]	PAN C, WANG QL, ZHENG YF, et al. Progress in monitoring and treatment strategies for adverse reactions of tumor immunological checkpoint inhibitors[J]. China Med Herald, 2019, 16(7): 41-44. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY201907011.htm 潘岑, 王庆兰, 郑永法, 等. 肿瘤免疫检查点抑制剂不良反应的监测与处理策略研究进展[J]. 中国医药导报, 2019, 16(7): 41-44. https://www.cnki.com.cn/Article/CJFDTOTAL-YYCY201907011.htm
[7]	ZHANG QY, CHEN LL, GAO F, et al. Pathological features of immune-mediated hepatitis due to immune checkpoint inhibitors and anti-angiogenesis targeted therapy[J]. Chin J Pathol, 2020, 49(4): 329-335. (in Chinese) http://d.wanfangdata.com.cn/periodical/zhblx202004005 章琼燕, 陈伶俐, 高峰, 等. 免疫检查点抑制剂治疗后肝功能异常的组织病理学分析[J]. 中华病理学杂志, 2020, 49(4): 329-335. http://d.wanfangdata.com.cn/periodical/zhblx202004005
[8]	TROTTI A, BYHARDT R, STETZ J, et al. Common toxicity criteria: Version 2.0. an improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy[J]. Int J Radiat Oncol Biol Phys, 2000, 47(1): 13-47. DOI: 10.1016/S0360-3016(99)00559-3
[9]	REED GB Jr, COX AJ Jr. The human liver after radiation injury. A form of veno-occlusive disease[J]. Am J Pathol, 1966, 48(4): 597-611.
[10]	WU DC. Radioactive medicine[M]. Beijing: Military Medical Science Press, 2001: 104-105. (in Chinese) 吴德昌. 放射医学[M]. 北京:军事医学科学出版社, 2001: 104-105.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(4) / Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (238) PDF downloads(38)

Differential diagnosis and treatment of jaundice after comprehensive treatment of advanced primary liver cancer: A case report

DOI: 10.3969/j.issn.1001-5256.2021.02.030

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Differential diagnosis and treatment of jaundice after comprehensive treatment of advanced primary liver cancer: A case report

DOI: 10.3969/j.issn.1001-5256.2021.02.030

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content